

Hanxiao You

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/956318/hanxiao-you-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

88
citations

4
h-index

9
g-index

18
ext. papers

150
ext. citations

5.3
avg, IF

2.52
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 13 | Prognostic factors of systemic lupus erythematosus patients with pulmonary embolism: An 11-year cohort study.. <i>Lupus</i> , 2022 , 9612033221095149 | 2.6 | 1 |
| 12 | Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study. <i>Lupus</i> , 2021 , 30, 1459-1468 | 2.6 | 1 |
| 11 | Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021 , 60, 2472-2477 | 3.9 | 5 |
| 10 | Early Initiation of Anticoagulation Improves the Long-Term Prognosis in Patients With Antiphospholipid Syndrome Associated Portal Vein Thrombosis. <i>Frontiers in Medicine</i> , 2021 , 8, 630660 | 4.9 | |
| 9 | Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021 , 12, 648881 | 8.4 | 0 |
| 8 | Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1847-1855 | 9.5 | 4 |
| 7 | Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021 , 12, 741369 | 8.4 | 3 |
| 6 | Chinese SLE Treatment and Research Group Registry(CSTAR)XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021 , 23, 20 | 5.7 | 0 |
| 5 | Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis. <i>Journal of Immunology Research</i> , 2020 , 2020, 2156762 | 4.5 | 2 |
| 4 | JAK Inhibitors: Prospects in Connective Tissue Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2020 , 59, 334-351 | 12.3 | 38 |
| 3 | Characteristics and risk factors of pulmonary embolism in patients with systemic lupus erythematosus: a case control study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 940-948 | 2.2 | 2 |
| 2 | Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1441-1443 | 2.4 | 28 |
| 1 | The Effects of Genetic Polymorphism on Treatment Response of Recombinant Human Growth Hormone. <i>Current Drug Metabolism</i> , 2018 , 19, 1159-1167 | 3.5 | 3 |